KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
First quarter 2024 net revenues of $8.2 million, an 11% increase YoY and record high quarterly revenues. Core business (U.S. and International) experienced 14% growth YoY, driven by SCIg market growth, share gains, and geographic expansion. Entered a Novel Therapies collaboration with an oncology drug therapy, bringing total collaborations to 16. Gross profit increased by 23% to $5.1 million, with a gross margin of 62% showing improvement YoY. Ending cash balance of $10.8 million and quarterly cash usage of $0.7 million, reflecting increased operating leverage and working capital improvements. Reaffirmed full year 2024 revenue guidance of $31.2-$32.2 million, representing growth of 10-13% YoY.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.